METASTATIC BREAST CANCER

This study tests whether adding belzutifan to fulvestrant can slow or stop the growth of a certain type of advanced breast cancer (ER+/HER2-) that has worsened despite hormone therapy. About 120 adults with inoperable or metastatic disease will receive either the new combination …

This study offers continued access to the targeted cancer drug ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis trial. About 134 participants will keep taking ribociclib, sometimes with other hormone therapies, while re…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-phase study tests a cancer vaccine (PVX-410) alone or with the immunotherapy drug pembrolizumab in 20 women with metastatic triple negative breast cancer who have a specific genetic marker (HLA-A2). The goal is to see if the vaccine safely boosts the immune system to f…

This study tests a drug called elacestrant combined with other medicines in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find safe doses and see if these combinations can slow down cancer growth. About 435 adults with metastatic breast cancer wi…

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…

This phase 2 trial tests whether continuing the drug palbociclib (Ibrance) while switching to a different hormone therapy, fulvestrant (Faslodex), can help control metastatic breast cancer in people whose disease has worsened on palbociclib plus an aromatase inhibitor. The study …

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This phase 2 trial is testing the drug taletrectinib in people with a rare, advanced form of breast cancer called invasive lobular carcinoma that has a specific gene change (CDH1 mutation). The study aims to see if the drug can shrink tumors or slow the cancer's growth. The trial…

This study tests a new drug, DB-1303, against standard chemotherapy in about 540 people with a specific type of advanced breast cancer (HER2-low, hormone receptor-positive) that has stopped responding to hormone therapy. The main goal is to see if DB-1303 can delay cancer growth …

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants receive the drug intravenously, and doctors monitor tumor response using brain…

This Phase 2 trial tests the drug elacestrant in 61 people with estrogen receptor-positive, HER2-negative metastatic breast cancer who have not previously used CDK4/6 inhibitors. Participants take a daily pill for about 6 months. The study aims to see if the drug can delay cancer…

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…

This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it …

This study tests whether a highly focused type of radiation called stereotactic body radiation therapy (SBRT) can delay cancer progression in women with metastatic breast cancer who are starting their first treatment. About 154 participants will receive either standard therapy al…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receiv…

This study tests a new treatment for women with metastatic breast cancer that has spread. It combines specially trained immune cells (HER2 BATs) that attack cancer cells with a drug called pembrolizumab that helps the immune system work better. The goal is to find a safe dose and…

This study looks at whether people with HER2-positive metastatic breast cancer who have had their cancer controlled for at least three years can safely stop their anti-HER2 therapy. About 82 participants will either stop or continue treatment to see if the cancer stays away for a…

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) can safely shrink tumors in people with triple-negative breast cancer that has spread. About 50 adults with advanced or metastatic disease will receive the combination. The goa…

This study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …

This phase 3 study tests a drug called sacituzumab govitecan (Trodelvy) against standard chemotherapy in 331 Asian patients with HR+/HER2- metastatic breast cancer who have already tried at least two prior chemotherapies. The goal is to see if the new drug can delay cancer growth…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This phase 2 study tests the drug abemaciclib, either alone or with tamoxifen, in 234 women with a specific type of advanced breast cancer (HR+, HER2-). The goal is to see if these treatments can slow cancer growth in patients whose disease has progressed after prior therapies. P…

This study tests whether a new drug called RPH-051 works as well as the approved drug Perjeta when both are given with standard chemotherapy and another targeted therapy for people with HER2-positive breast cancer that has spread or cannot be removed. About 246 participants will …

This study tests whether a combination of two targeted pills (fluorizoparib and apatinib) works better than standard chemotherapy for people with a specific genetic type of advanced breast cancer (HRD-positive, HER2-negative). About 200 participants will be randomly assigned to e…

This study tests a new combination of two drugs—niraparib and trastuzumab—in people with metastatic HER2-positive breast cancer, an aggressive form of the disease. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth. About 46 women with advanced ca…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a common type of advanced breast cancer (HR+/HER2-). About 110 participants receive either the combination or sacituzumab alone. The goal is to see if the combo delays cancer growt…

This phase 2 study tests the drug olaparib in 114 people with metastatic breast cancer whose tumors have mutations in certain DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, and others). Olaparib is a PARP inhibitor that may kill cancer cells by blocking their ability to fix dam…

This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the hormone therapy fulvestrant (Faslodex) can help control advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative. The study includes 47 adults and …

This phase 3 trial tests whether giving denosumab every 12 weeks instead of every 4 weeks can still prevent bone complications (like fractures or spinal cord compression) in people with metastatic breast or prostate cancer. About 1,380 participants with bone metastases will be ra…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This study tests whether adding a targeted drug called AZD5363 to the standard hormone therapy fulvestrant can slow the growth of advanced estrogen-receptor-positive (ER+) breast cancer. It involves 149 postmenopausal women whose cancer has worsened despite prior treatment with a…

This study tests whether a very low-carb (ketogenic) diet, a low-carb diet, or the diabetes drug canagliflozin can prevent high blood sugar and possibly make standard cancer therapy more effective. It involves 15 people with advanced, hormone-receptor-positive breast cancer that …

This phase 2 trial tests three drug combinations—fulvestrant alone, fulvestrant plus palbociclib, and fulvestrant plus palbociclib plus avelumab—in 220 people with ER+/HER2- metastatic breast cancer that has progressed after prior CDK inhibitor therapy. The goal is to see which c…

This study tests a combination of two drugs, lenvatinib and letrozole, given before surgery to postmenopausal women with a common type of breast cancer (hormone receptor positive). The goal is to see if the drugs can shrink the tumor enough to improve surgical outcomes. About 40 …

This study tests an oral chemotherapy drug called Lonsurf in people with metastatic breast cancer that has spread. The trial includes two groups: those who have had a certain type of chemo before and those who haven't. Researchers want to see if Lonsurf can stop the cancer from g…

This phase 3 trial tests whether a combination of the targeted drug abemaciclib plus hormone therapy works as well as standard chemotherapy for women with ER+ HER2- breast cancer that has spread to the liver, lungs, or other organs. About 180 participants will be randomly assigne…

This phase 2 trial tests whether a PET scan using a radioactive form of estrogen (FES) can predict how well endocrine therapy works in 99 women with newly diagnosed metastatic breast cancer. The scan lights up cancer cells that have estrogen receptors, helping doctors see if the …

This study tested whether a special PET scan using a radioactive tracer can predict how well patients with advanced HER2-positive breast cancer respond to the drug T-DM1. Ten women with cancer that had spread to other parts of the body received the scan before treatment. The goal…

This study is testing whether a 9-month, individually tailored exercise program can reduce physical fatigue and improve quality of life in 357 people with stage IV breast cancer. Participants work with a trained instructor to follow a personalized exercise plan. The main goal is …

This study tests whether eating only within a 10-hour window each day can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty makes it harder to recover from stress and can lead to loss of independence. The trial will enroll 30 participa…

This study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need…

This study at Johns Hopkins is testing whether genetic information from a blood sample can match what is found in a tumor biopsy for people with metastatic breast cancer. Researchers will use the results to suggest personalized treatment options. The goal is to see if a simple bl…

This study looks at how age changes the way the body handles a breast cancer drug called nab-paclitaxel. Researchers are studying 40 people with metastatic breast cancer to see if older patients process the drug differently. The goal is to make chemotherapy safer and more effecti…

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …

This study tracks 65 people with metastatic breast cancer to see if a blood test that finds cancer cells (called circulating tumor cells) helps doctors choose the right treatment and check if it's working. Participants give blood samples and doctors answer surveys about how usefu…

This study looks at how the drug tucatinib enters and works in HER2+ cancers that have spread to the brain. Nine adults with breast, lung, or other cancers will take tucatinib before brain surgery. Researchers will test tumor samples to find genetic clues about why some cancers s…

This study looks at real-world treatment patterns and outcomes for nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. Researchers will analyze data from medical records to understand how patients are treated and how long they live. The goal is to…

This study is testing commercially available antibodies to see if they can identify breast cancer markers in blood samples. Researchers will collect blood from 84 people, including breast cancer patients and healthy volunteers. The goal is to improve detection of circulating tumo…

This study looks at whether a blood test that tracks tumor DNA (ctDNA) can help doctors switch treatments earlier in people with metastatic breast cancer. The goal is to see if acting on a molecular signal of progression, before symptoms or scans show it, can keep the cancer unde…

This study looks at 197 women with advanced breast cancer to compare survival between those whose tumors lost estrogen receptors (ER) and those with triple-negative disease. Researchers used a special PET scan to track receptor changes. The goal is to understand how these changes…

This study looks at whether simple blood tests can tell if a woman's metastatic breast cancer is stable, so she can skip some routine scans. About 97 women with ER-positive/HER2-negative cancer will give blood samples at each scan visit. The goal is to create a smart algorithm th…

This study tracks how much time people with advanced breast or ovarian cancer spend on care-related tasks like appointments, travel, and managing symptoms. Participants use a smartphone app for 28 days to log activities and complete surveys about their well-being. The goal is to …

This early-phase study tests whether a special PET scan using a tracer called FLT can show how breast cancer tumors respond to a combination of two drugs, ribociclib and paclitaxel. The study involves 20 people with metastatic breast cancer that has spread beyond the liver and bo…